Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05417971 · ClinicalTrials.gov registry record
Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation
A clinical trial of Hematologic Malignancy, sponsored by Northside Hospital.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT05417971 is a study of Hematologic Malignancy that is actively recruiting participants, run by Northside Hospital. The registered enrollment target is 20 participants, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05417971, a study of Hematologic Malignancy, is actively recruiting participants, sponsored by Northside Hospital.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.
Conditions Studied
Interventions
- OTHER Fludarabine
Study Locations (1)
Georgia
- Caitlin Guzowski - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-08-29 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05417971
The ClinicalTrials.gov registry entry for NCT05417971 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (91% lower). The listed sponsor is Northside Hospital, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Fludarabine is the first listed.
NCT05417971 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05417971 about?
NCT05417971 is a clinical study titled "Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation". This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.
What is the current status of trial NCT05417971?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2022-08-29. Estimated completion is 2026-12-31.
What conditions does trial NCT05417971 study?
This clinical trial studies the following conditions: Hematologic Malignancy.
What interventions are being tested in trial NCT05417971?
The interventions under investigation include: Fludarabine (OTHER).
Who is sponsoring clinical trial NCT05417971?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05417971 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
RECRUITING
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.